Uncategorized
Inotek’s phase 3 MATrX-1 trial of trabodenoson fails to meet primary endpoint
MATrX-1, a phase 3 trial of trabodenoson for the treatment of primary open-angle glaucoma or ocular hypertension, failed to achieve its primary endpoint of superiority in reduction of IOP compared with placebo at all time points, according to an Inotek Pharmaceuticals press release.The randomized, double-masked, placebo-controlled trial assessed the safety, efficacy and tolerability of three doses of trabodenoson in 303 subjects. Patients’ IOP was measured on days 14, 28, 42 and 84 at four time points during each of these days: 8 a.m., 10 a.m., 12 p.m. and 4 p.m. (Read more...)